APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Rhabdomyosarcoma Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Rhabdomyosarcoma Drug Market Analysis and Forecast 2026-2032

Report ID 174032740222 December 2025204 pages

Choose your research edition.

Industry ResearchRhabdomyosarcoma Drug Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Rhabdomyosarcoma Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Rhabdomyosarcoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rhabdomyosarcoma Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Rhabdomyosarcoma Drug Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Rhabdomyosarcoma Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Rhabdomyosarcoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Rhabdomyosarcoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Rhabdomyosarcoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Rhabdomyosarcoma Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Rhabdomyosarcoma Drug include Eisai Co Ltd, Novartis AG, Pfizer Inc, Bristol-Myers Squibb Co, Tarveda Therapeutics Inc, Taiwan Liposome Company Ltd, Taiho Pharmaceutical Co Ltd, Noxxon Pharma AG and NantKwest Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Rhabdomyosarcoma Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Rhabdomyosarcoma Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Rhabdomyosarcoma Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rhabdomyosarcoma Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Rhabdomyosarcoma Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Rhabdomyosarcoma Drug sales, projected growth trends, production technology, application and end-user industry.

Rhabdomyosarcoma Drug Segment by Company

Eisai Co Ltd

Novartis AG

Pfizer Inc

Bristol-Myers Squibb Co

Tarveda Therapeutics Inc

Taiwan Liposome Company Ltd

Taiho Pharmaceutical Co Ltd

Noxxon Pharma AG

NantKwest Inc

MacroGenics Inc

Ipsen SA

Iproteos SL

Exelixis Inc

Epizyme Inc

Celgene Corp

Boehringer Ingelheim GmbH

Bellicum Pharmaceuticals Inc

Rhabdomyosarcoma Drug Segment by Type

ARI-4175

AT-69

Celyvir

Enoblituzumab

Axitinib

Crizotinib

Others

Rhabdomyosarcoma Drug Segment by Application

Clinic

Hospital

Research Center

Others

Rhabdomyosarcoma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rhabdomyosarcoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rhabdomyosarcoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rhabdomyosarcoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Rhabdomyosarcoma Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Rhabdomyosarcoma Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Rhabdomyosarcoma Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Rhabdomyosarcoma Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. ARI-4175 Major Manufacturers Table 3. AT-69 Major Manufacturers Table 4. Celyvir Major Manufacturers Table 5. Enoblituzumab Major Manufacturers Table 6. Axitinib Major Manufacturers Table 7. Crizotinib Major Manufacturers Table 8. Others Major Manufacturers Table 9. Global Rhabdomyosarcoma Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Clinic Major Manufacturers Table 11. Hospital Major Manufacturers Table 12. Research Center Major Manufacturers Table 13. Others Major Manufacturers Table 14. Rhabdomyosarcoma Drug Industry Trends Table 15. Rhabdomyosarcoma Drug Industry Drivers Table 16. Rhabdomyosarcoma Drug Industry Opportunities and Challenges Table 17. Rhabdomyosarcoma Drug Industry Restraints Table 18. Global Rhabdomyosarcoma Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Rhabdomyosarcoma Drug Revenue by Region (2021-2026) & (US$ Million) Table 20. Global Rhabdomyosarcoma Drug Revenue by Region (2027-2032) & (US$ Million) Table 21. Global Rhabdomyosarcoma Drug Revenue Market Share by Region (2021-2026) Table 22. Global Rhabdomyosarcoma Drug Revenue Market Share by Region (2027-2032) Table 23. Global Rhabdomyosarcoma Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 24. Global Rhabdomyosarcoma Drug Sales by Region (2021-2026) & (k units) Table 25. Global Rhabdomyosarcoma Drug Sales by Region (2027-2032) & (k units) Table 26. Global Rhabdomyosarcoma Drug Sales Market Share by Region (2021-2026) Table 27. Global Rhabdomyosarcoma Drug Sales Market Share by Region (2027-2032) Table 28. Global Rhabdomyosarcoma Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Rhabdomyosarcoma Drug Revenue Market Share by Manufacturers (2021-2026) Table 30. Global Rhabdomyosarcoma Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 31. Global Rhabdomyosarcoma Drug Sales Market Share by Manufacturers (2021-2026) Table 32. Global Rhabdomyosarcoma Drug Sales Price (US$/unit) of Manufacturers (2021-2026) Table 33. Global Rhabdomyosarcoma Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 34. Global Rhabdomyosarcoma Drug Key Manufacturers Manufacturing Sites & Headquarters Table 35. Global Rhabdomyosarcoma Drug Manufacturers, Product Type & Application Table 36. Global Rhabdomyosarcoma Drug Manufacturers' Establishment Date Table 37. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 38. Global Rhabdomyosarcoma Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Rhabdomyosarcoma Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Rhabdomyosarcoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 41. Global Rhabdomyosarcoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 42. Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2021-2026) Table 43. Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2027-2032) Table 44. Global Rhabdomyosarcoma Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 45. Global Rhabdomyosarcoma Drug Sales by Type (2021-2026) & (k units) Table 46. Global Rhabdomyosarcoma Drug Sales by Type (2027-2032) & (k units) Table 47. Global Rhabdomyosarcoma Drug Sales Market Share by Type (2021-2026) Table 48. Global Rhabdomyosarcoma Drug Sales Market Share by Type (2027-2032) Table 49. Global Rhabdomyosarcoma Drug Price by Type (2021-2026) & (US$/unit) Table 50. Global Rhabdomyosarcoma Drug Price by Type (2027-2032) & (US$/unit) Table 51. Global Rhabdomyosarcoma Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Rhabdomyosarcoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 53. Global Rhabdomyosarcoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 54. Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2021-2026) Table 55. Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2027-2032) Table 56. Global Rhabdomyosarcoma Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 57. Global Rhabdomyosarcoma Drug Sales by Application (2021-2026) & (k units) Table 58. Global Rhabdomyosarcoma Drug Sales by Application (2027-2032) & (k units) Table 59. Global Rhabdomyosarcoma Drug Sales Market Share by Application (2021-2026) Table 60. Global Rhabdomyosarcoma Drug Sales Market Share by Application (2027-2032) Table 61. Global Rhabdomyosarcoma Drug Price by Application (2021-2026) & (US$/unit) Table 62. Global Rhabdomyosarcoma Drug Price by Application (2027-2032) & (US$/unit) Table 63. Eisai Co Ltd Company Information Table 64. Eisai Co Ltd Business Overview Table 65. Eisai Co Ltd Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Eisai Co Ltd Rhabdomyosarcoma Drug Product Portfolio Table 67. Eisai Co Ltd Recent Development Table 68. Novartis AG Company Information Table 69. Novartis AG Business Overview Table 70. Novartis AG Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Novartis AG Rhabdomyosarcoma Drug Product Portfolio Table 72. Novartis AG Recent Development Table 73. Pfizer Inc Company Information Table 74. Pfizer Inc Business Overview Table 75. Pfizer Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Pfizer Inc Rhabdomyosarcoma Drug Product Portfolio Table 77. Pfizer Inc Recent Development Table 78. Bristol-Myers Squibb Co Company Information Table 79. Bristol-Myers Squibb Co Business Overview Table 80. Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Product Portfolio Table 82. Bristol-Myers Squibb Co Recent Development Table 83. Tarveda Therapeutics Inc Company Information Table 84. Tarveda Therapeutics Inc Business Overview Table 85. Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Product Portfolio Table 87. Tarveda Therapeutics Inc Recent Development Table 88. Taiwan Liposome Company Ltd Company Information Table 89. Taiwan Liposome Company Ltd Business Overview Table 90. Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Product Portfolio Table 92. Taiwan Liposome Company Ltd Recent Development Table 93. Taiho Pharmaceutical Co Ltd Company Information Table 94. Taiho Pharmaceutical Co Ltd Business Overview Table 95. Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Product Portfolio Table 97. Taiho Pharmaceutical Co Ltd Recent Development Table 98. Noxxon Pharma AG Company Information Table 99. Noxxon Pharma AG Business Overview Table 100. Noxxon Pharma AG Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Noxxon Pharma AG Rhabdomyosarcoma Drug Product Portfolio Table 102. Noxxon Pharma AG Recent Development Table 103. NantKwest Inc Company Information Table 104. NantKwest Inc Business Overview Table 105. NantKwest Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. NantKwest Inc Rhabdomyosarcoma Drug Product Portfolio Table 107. NantKwest Inc Recent Development Table 108. MacroGenics Inc Company Information Table 109. MacroGenics Inc Business Overview Table 110. MacroGenics Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. MacroGenics Inc Rhabdomyosarcoma Drug Product Portfolio Table 112. MacroGenics Inc Recent Development Table 113. Ipsen SA Company Information Table 114. Ipsen SA Business Overview Table 115. Ipsen SA Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Ipsen SA Rhabdomyosarcoma Drug Product Portfolio Table 117. Ipsen SA Recent Development Table 118. Iproteos SL Company Information Table 119. Iproteos SL Business Overview Table 120. Iproteos SL Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Iproteos SL Rhabdomyosarcoma Drug Product Portfolio Table 122. Iproteos SL Recent Development Table 123. Exelixis Inc Company Information Table 124. Exelixis Inc Business Overview Table 125. Exelixis Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Exelixis Inc Rhabdomyosarcoma Drug Product Portfolio Table 127. Exelixis Inc Recent Development Table 128. Epizyme Inc Company Information Table 129. Epizyme Inc Business Overview Table 130. Epizyme Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Epizyme Inc Rhabdomyosarcoma Drug Product Portfolio Table 132. Epizyme Inc Recent Development Table 133. Celgene Corp Company Information Table 134. Celgene Corp Business Overview Table 135. Celgene Corp Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Celgene Corp Rhabdomyosarcoma Drug Product Portfolio Table 137. Celgene Corp Recent Development Table 138. Boehringer Ingelheim GmbH Company Information Table 139. Boehringer Ingelheim GmbH Business Overview Table 140. Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Product Portfolio Table 142. Boehringer Ingelheim GmbH Recent Development Table 143. Bellicum Pharmaceuticals Inc Company Information Table 144. Bellicum Pharmaceuticals Inc Business Overview Table 145. Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Product Portfolio Table 147. Bellicum Pharmaceuticals Inc Recent Development Table 148. North America Rhabdomyosarcoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 149. North America Rhabdomyosarcoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 150. North America Rhabdomyosarcoma Drug Sales by Type (2021-2026) & (k units) Table 151. North America Rhabdomyosarcoma Drug Sales by Type (2027-2032) & (k units) Table 152. North America Rhabdomyosarcoma Drug Sales Price by Type (2021-2026) & (US$/unit) Table 153. North America Rhabdomyosarcoma Drug Sales Price by Type (2027-2032) & (US$/unit) Table 154. North America Rhabdomyosarcoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 155. North America Rhabdomyosarcoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 156. North America Rhabdomyosarcoma Drug Sales by Application (2021-2026) & (k units) Table 157. North America Rhabdomyosarcoma Drug Sales by Application (2027-2032) & (k units) Table 158. North America Rhabdomyosarcoma Drug Sales Price by Application (2021-2026) & (US$/unit) Table 159. North America Rhabdomyosarcoma Drug Sales Price by Application (2027-2032) & (US$/unit) Table 160. North America Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. North America Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 162. North America Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 163. North America Rhabdomyosarcoma Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 164. North America Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 165. North America Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 166. North America Rhabdomyosarcoma Drug Sales Price by Country (2021-2026) & (US$/unit) Table 167. North America Rhabdomyosarcoma Drug Sales Price by Country (2027-2032) & (US$/unit) Table 168. United States Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 169. Canada Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 170. Mexico Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 171. Europe Rhabdomyosarcoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 172. Europe Rhabdomyosarcoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 173. Europe Rhabdomyosarcoma Drug Sales by Type (2021-2026) & (k units) Table 174. Europe Rhabdomyosarcoma Drug Sales by Type (2027-2032) & (k units) Table 175. Europe Rhabdomyosarcoma Drug Sales Price by Type (2021-2026) & (US$/unit) Table 176. Europe Rhabdomyosarcoma Drug Sales Price by Type (2027-2032) & (US$/unit) Table 177. Europe Rhabdomyosarcoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 178. Europe Rhabdomyosarcoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 179. Europe Rhabdomyosarcoma Drug Sales by Application (2021-2026) & (k units) Table 180. Europe Rhabdomyosarcoma Drug Sales by Application (2027-2032) & (k units) Table 181. Europe Rhabdomyosarcoma Drug Sales Price by Application (2021-2026) & (US$/unit) Table 182. Europe Rhabdomyosarcoma Drug Sales Price by Application (2027-2032) & (US$/unit) Table 183. Europe Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 184. Europe Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 185. Europe Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 186. Europe Rhabdomyosarcoma Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 187. Europe Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 188. Europe Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 189. Europe Rhabdomyosarcoma Drug Sales Price by Country (2021-2026) & (US$/unit) Table 190. Europe Rhabdomyosarcoma Drug Sales Price by Country (2027-2032) & (US$/unit) Table 191. Germany Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 192. France Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 193. U.K. Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 194. Italy Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 195. Russia Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 196. Spain Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 197. Netherlands Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 198. Switzerland Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 199. Sweden Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 200. Poland Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 201. China Rhabdomyosarcoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 202. China Rhabdomyosarcoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 203. China Rhabdomyosarcoma Drug Sales by Type (2021-2026) & (k units) Table 204. China Rhabdomyosarcoma Drug Sales by Type (2027-2032) & (k units) Table 205. China Rhabdomyosarcoma Drug Sales Price by Type (2021-2026) & (US$/unit) Table 206. China Rhabdomyosarcoma Drug Sales Price by Type (2027-2032) & (US$/unit) Table 207. China Rhabdomyosarcoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 208. China Rhabdomyosarcoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 209. China Rhabdomyosarcoma Drug Sales by Application (2021-2026) & (k units) Table 210. China Rhabdomyosarcoma Drug Sales by Application (2027-2032) & (k units) Table 211. China Rhabdomyosarcoma Drug Sales Price by Application (2021-2026) & (US$/unit) Table 212. China Rhabdomyosarcoma Drug Sales Price by Application (2027-2032) & (US$/unit) Table 213. Asia Rhabdomyosarcoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 214. Asia Rhabdomyosarcoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 215. Asia Rhabdomyosarcoma Drug Sales by Type (2021-2026) & (k units) Table 216. Asia Rhabdomyosarcoma Drug Sales by Type (2027-2032) & (k units) Table 217. Asia Rhabdomyosarcoma Drug Sales Price by Type (2021-2026) & (US$/unit) Table 218. Asia Rhabdomyosarcoma Drug Sales Price by Type (2027-2032) & (US$/unit) Table 219. Asia Rhabdomyosarcoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 220. Asia Rhabdomyosarcoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 221. Asia Rhabdomyosarcoma Drug Sales by Application (2021-2026) & (k units) Table 222. Asia Rhabdomyosarcoma Drug Sales by Application (2027-2032) & (k units) Table 223. Asia Rhabdomyosarcoma Drug Sales Price by Application (2021-2026) & (US$/unit) Table 224. Asia Rhabdomyosarcoma Drug Sales Price by Application (2027-2032) & (US$/unit) Table 225. Asia Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 226. Asia Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 227. Asia Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 228. Asia Rhabdomyosarcoma Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 229. Asia Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 230. Asia Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 231. Asia Rhabdomyosarcoma Drug Sales Price by Country (2021-2026) & (US$/unit) Table 232. Asia Rhabdomyosarcoma Drug Sales Price by Country (2027-2032) & (US$/unit) Table 233. Japan Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 234. South Korea Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 235. India Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 236. Australia Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 237. Taiwan Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 238. Southeast Asia Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 239. SAMEA Rhabdomyosarcoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 240. SAMEA Rhabdomyosarcoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 241. SAMEA Rhabdomyosarcoma Drug Sales by Type (2021-2026) & (k units) Table 242. SAMEA Rhabdomyosarcoma Drug Sales by Type (2027-2032) & (k units) Table 243. SAMEA Rhabdomyosarcoma Drug Sales Price by Type (2021-2026) & (US$/unit) Table 244. SAMEA Rhabdomyosarcoma Drug Sales Price by Type (2027-2032) & (US$/unit) Table 245. SAMEA Rhabdomyosarcoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 246. SAMEA Rhabdomyosarcoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 247. SAMEA Rhabdomyosarcoma Drug Sales by Application (2021-2026) & (k units) Table 248. SAMEA Rhabdomyosarcoma Drug Sales by Application (2027-2032) & (k units) Table 249. SAMEA Rhabdomyosarcoma Drug Sales Price by Application (2021-2026) & (US$/unit) Table 250. SAMEA Rhabdomyosarcoma Drug Sales Price by Application (2027-2032) & (US$/unit) Table 251. SAMEA Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 252. SAMEA Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 253. SAMEA Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 254. SAMEA Rhabdomyosarcoma Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 255. SAMEA Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 256. SAMEA Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 257. SAMEA Rhabdomyosarcoma Drug Sales Price by Country (2021-2026) & (US$/unit) Table 258. SAMEA Rhabdomyosarcoma Drug Sales Price by Country (2027-2032) & (US$/unit) Table 259. Brazil Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 260. Argentina Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 261. Chile Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 262. Colombia Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 263. Peru Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 264. Saudi Arabia Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 265. Israel Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 266. UAE Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 267. Turkey Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 268. Iran Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 269. Egypt Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Table 270. Key Raw Materials Table 271. Raw Materials Key Suppliers Table 272. Rhabdomyosarcoma Drug Distributors List Table 273. Rhabdomyosarcoma Drug Customers List Table 274. Research Programs/Design for This Report Table 275. Authors List of This Report Table 276. Secondary Sources Table 277. Primary Sources List of Figures Figure 1. Rhabdomyosarcoma Drug Image Figure 2. Global Rhabdomyosarcoma Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rhabdomyosarcoma Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. ARI-4175 Image Figure 5. AT-69 Image Figure 6. Celyvir Image Figure 7. Enoblituzumab Image Figure 8. Axitinib Image Figure 9. Crizotinib Image Figure 10. Others Image Figure 11. Global Rhabdomyosarcoma Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Rhabdomyosarcoma Drug Market Size Share 2021 VS 2025 VS 2032 Figure 13. Clinic Image Figure 14. Hospital Image Figure 15. Research Center Image Figure 16. Others Image Figure 17. Global Rhabdomyosarcoma Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Figure 19. Global Rhabdomyosarcoma Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Rhabdomyosarcoma Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 21. Global Rhabdomyosarcoma Drug Revenue Market Share by Region (2021-2032) Figure 22. Global Rhabdomyosarcoma Drug Sales (2021-2032) & (k units) Figure 23. Global Rhabdomyosarcoma Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 24. Global Rhabdomyosarcoma Drug Sales Market Share by Region (2021-2032) Figure 25. US & Canada & Mexico Rhabdomyosarcoma Drug Sales YoY (2021-2032) & (k units) Figure 26. Europe Rhabdomyosarcoma Drug Sales YoY (2021-2032) & (k units) Figure 27. China Rhabdomyosarcoma Drug Sales YoY (2021-2032) & (k units) Figure 28. Asia (Excluding China) Rhabdomyosarcoma Drug Sales YoY (2021-2032) & (k units) Figure 29. South America, Middle East and Africa Rhabdomyosarcoma Drug Sales YoY (2021-2032) & (k units) Figure 30. Global Rhabdomyosarcoma Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 31. Global Rhabdomyosarcoma Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 32. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Global Rhabdomyosarcoma Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Rhabdomyosarcoma Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2021-2032) Figure 36. Global Rhabdomyosarcoma Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 37. Global Rhabdomyosarcoma Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 38. Global Rhabdomyosarcoma Drug Sales Market Share by Type (2021-2032) Figure 39. Global Rhabdomyosarcoma Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 40. Global Rhabdomyosarcoma Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2021-2032) Figure 42. Global Rhabdomyosarcoma Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 43. Global Rhabdomyosarcoma Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 44. Global Rhabdomyosarcoma Drug Sales Market Share by Application (2021-2032) Figure 45. North America Rhabdomyosarcoma Drug Revenue Share by Type (2021-2032) Figure 46. North America Rhabdomyosarcoma Drug Sales Share by Type (2021-2032) Figure 47. North America Rhabdomyosarcoma Drug Revenue Share by Application (2021-2032) Figure 48. North America Rhabdomyosarcoma Drug Sales Share by Application (2021-2032) Figure 49. North America Rhabdomyosarcoma Drug Revenue Share by Country (2021-2032) Figure 50. North America Rhabdomyosarcoma Drug Sales Share by Country (2021-2032) Figure 51. Europe Rhabdomyosarcoma Drug Revenue Share by Type (2021-2032) Figure 52. Europe Rhabdomyosarcoma Drug Sales Share by Type (2021-2032) Figure 53. Europe Rhabdomyosarcoma Drug Revenue Share by Application (2021-2032) Figure 54. Europe Rhabdomyosarcoma Drug Sales Share by Application (2021-2032) Figure 55. Europe Rhabdomyosarcoma Drug Revenue Share by Country (2021-2032) Figure 56. Europe Rhabdomyosarcoma Drug Sales Share by Country (2021-2032) Figure 57. China Rhabdomyosarcoma Drug Revenue Share by Type (2021-2032) Figure 58. China Rhabdomyosarcoma Drug Sales Share by Type (2021-2032) Figure 59. China Rhabdomyosarcoma Drug Revenue Share by Application (2021-2032) Figure 60. China Rhabdomyosarcoma Drug Sales Share by Application (2021-2032) Figure 61. Asia Rhabdomyosarcoma Drug Revenue Share by Type (2021-2032) Figure 62. Asia Rhabdomyosarcoma Drug Sales Share by Type (2021-2032) Figure 63. Asia Rhabdomyosarcoma Drug Revenue Share by Application (2021-2032) Figure 64. Asia Rhabdomyosarcoma Drug Sales Share by Application (2021-2032) Figure 65. Asia Rhabdomyosarcoma Drug Revenue Share by Country (2021-2032) Figure 66. Asia Rhabdomyosarcoma Drug Sales Share by Country (2021-2032) Figure 67. SAMEA Rhabdomyosarcoma Drug Revenue Share by Type (2021-2032) Figure 68. SAMEA Rhabdomyosarcoma Drug Sales Share by Type (2021-2032) Figure 69. SAMEA Rhabdomyosarcoma Drug Revenue Share by Application (2021-2032) Figure 70. SAMEA Rhabdomyosarcoma Drug Sales Share by Application (2021-2032) Figure 71. SAMEA Rhabdomyosarcoma Drug Revenue Share by Country (2021-2032) Figure 72. SAMEA Rhabdomyosarcoma Drug Sales Share by Country (2021-2032) Figure 73. Rhabdomyosarcoma Drug Value Chain Figure 74. Manufacturing Cost Structure Figure 75. Rhabdomyosarcoma Drug Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Years Considered Figure 79. Research Process Figure 80. Key Executives Interviewed

Scope & coverage.

Types
  • ARI-4175
  • AT-69
  • Celyvir
  • Enoblituzumab
  • Axitinib
  • Crizotinib
  • Others
Applications
  • Clinic
  • Hospital
  • Research Center
  • Others
Companies covered
  • Eisai Co Ltd
  • Novartis AG
  • Pfizer Inc
  • Bristol-Myers Squibb Co
  • Tarveda Therapeutics Inc
  • Taiwan Liposome Company Ltd
  • Taiho Pharmaceutical Co Ltd
  • Noxxon Pharma AG
  • NantKwest Inc
  • MacroGenics Inc
  • Ipsen SA
  • Iproteos SL
  • Exelixis Inc
  • Epizyme Inc
  • Celgene Corp
  • Boehringer Ingelheim GmbH
  • Bellicum Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Rhabdomyosarcoma Drug Market by Type
  3. 1.2.1 Global Rhabdomyosarcoma Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 ARI-4175
  5. 1.2.3 AT-69
  6. 1.2.4 Celyvir
  7. 1.2.5 Enoblituzumab
  8. 1.2.6 Axitinib
  9. 1.2.7 Crizotinib
  10. 1.2.8 Others
  11. 1.3 Rhabdomyosarcoma Drug Market by Application
  12. 1.3.1 Global Rhabdomyosarcoma Drug Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Clinic
  14. 1.3.3 Hospital
  15. 1.3.4 Research Center
  16. 1.3.5 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Rhabdomyosarcoma Drug Market Dynamics
  1. 2.1 Rhabdomyosarcoma Drug Industry Trends
  2. 2.2 Rhabdomyosarcoma Drug Industry Drivers
  3. 2.3 Rhabdomyosarcoma Drug Industry Opportunities and Challenges
  4. 2.4 Rhabdomyosarcoma Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Rhabdomyosarcoma Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Rhabdomyosarcoma Drug Revenue by Region
  3. 3.2.1 Global Rhabdomyosarcoma Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Rhabdomyosarcoma Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Rhabdomyosarcoma Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Rhabdomyosarcoma Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Rhabdomyosarcoma Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Rhabdomyosarcoma Drug Sales by Region
  9. 3.4.1 Global Rhabdomyosarcoma Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Rhabdomyosarcoma Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Rhabdomyosarcoma Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Rhabdomyosarcoma Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Rhabdomyosarcoma Drug Revenue by Manufacturers
  2. 4.1.1 Global Rhabdomyosarcoma Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Rhabdomyosarcoma Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Rhabdomyosarcoma Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Rhabdomyosarcoma Drug Sales by Manufacturers
  6. 4.2.1 Global Rhabdomyosarcoma Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Rhabdomyosarcoma Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Rhabdomyosarcoma Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Rhabdomyosarcoma Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Rhabdomyosarcoma Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Rhabdomyosarcoma Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Rhabdomyosarcoma Drug Manufacturers, Product Type & Application
  13. 4.7 Global Rhabdomyosarcoma Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Rhabdomyosarcoma Drug Market CR5 and HHI
  16. 4.8.2 2025 Rhabdomyosarcoma Drug Tier 1, Tier 2, and Tier 3
5 Rhabdomyosarcoma Drug Market by Type
  1. 5.1 Global Rhabdomyosarcoma Drug Revenue by Type
  2. 5.1.1 Global Rhabdomyosarcoma Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Rhabdomyosarcoma Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Rhabdomyosarcoma Drug Sales by Type
  6. 5.2.1 Global Rhabdomyosarcoma Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Rhabdomyosarcoma Drug Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Rhabdomyosarcoma Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Rhabdomyosarcoma Drug Price by Type
6 Rhabdomyosarcoma Drug Market by Application
  1. 6.1 Global Rhabdomyosarcoma Drug Revenue by Application
  2. 6.1.1 Global Rhabdomyosarcoma Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Rhabdomyosarcoma Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Rhabdomyosarcoma Drug Sales by Application
  6. 6.2.1 Global Rhabdomyosarcoma Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Rhabdomyosarcoma Drug Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Rhabdomyosarcoma Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Rhabdomyosarcoma Drug Price by Application
7 Company Profiles
  1. 7.1 Eisai Co Ltd
  2. 7.1.1 Eisai Co Ltd Company Information
  3. 7.1.2 Eisai Co Ltd Business Overview
  4. 7.1.3 Eisai Co Ltd Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Eisai Co Ltd Rhabdomyosarcoma Drug Product Portfolio
  6. 7.1.5 Eisai Co Ltd Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Rhabdomyosarcoma Drug Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Pfizer Inc
  14. 7.3.1 Pfizer Inc Company Information
  15. 7.3.2 Pfizer Inc Business Overview
  16. 7.3.3 Pfizer Inc Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Inc Rhabdomyosarcoma Drug Product Portfolio
  18. 7.3.5 Pfizer Inc Recent Developments
  19. 7.4 Bristol-Myers Squibb Co
  20. 7.4.1 Bristol-Myers Squibb Co Company Information
  21. 7.4.2 Bristol-Myers Squibb Co Business Overview
  22. 7.4.3 Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Co Recent Developments
  25. 7.5 Tarveda Therapeutics Inc
  26. 7.5.1 Tarveda Therapeutics Inc Company Information
  27. 7.5.2 Tarveda Therapeutics Inc Business Overview
  28. 7.5.3 Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Product Portfolio
  30. 7.5.5 Tarveda Therapeutics Inc Recent Developments
  31. 7.6 Taiwan Liposome Company Ltd
  32. 7.6.1 Taiwan Liposome Company Ltd Company Information
  33. 7.6.2 Taiwan Liposome Company Ltd Business Overview
  34. 7.6.3 Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Product Portfolio
  36. 7.6.5 Taiwan Liposome Company Ltd Recent Developments
  37. 7.7 Taiho Pharmaceutical Co Ltd
  38. 7.7.1 Taiho Pharmaceutical Co Ltd Company Information
  39. 7.7.2 Taiho Pharmaceutical Co Ltd Business Overview
  40. 7.7.3 Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Product Portfolio
  42. 7.7.5 Taiho Pharmaceutical Co Ltd Recent Developments
  43. 7.8 Noxxon Pharma AG
  44. 7.8.1 Noxxon Pharma AG Company Information
  45. 7.8.2 Noxxon Pharma AG Business Overview
  46. 7.8.3 Noxxon Pharma AG Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Noxxon Pharma AG Rhabdomyosarcoma Drug Product Portfolio
  48. 7.8.5 Noxxon Pharma AG Recent Developments
  49. 7.9 NantKwest Inc
  50. 7.9.1 NantKwest Inc Company Information
  51. 7.9.2 NantKwest Inc Business Overview
  52. 7.9.3 NantKwest Inc Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 NantKwest Inc Rhabdomyosarcoma Drug Product Portfolio
  54. 7.9.5 NantKwest Inc Recent Developments
  55. 7.10 MacroGenics Inc
  56. 7.10.1 MacroGenics Inc Company Information
  57. 7.10.2 MacroGenics Inc Business Overview
  58. 7.10.3 MacroGenics Inc Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 MacroGenics Inc Rhabdomyosarcoma Drug Product Portfolio
  60. 7.10.5 MacroGenics Inc Recent Developments
  61. 7.11 Ipsen SA
  62. 7.11.1 Ipsen SA Company Information
  63. 7.11.2 Ipsen SA Business Overview
  64. 7.11.3 Ipsen SA Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Ipsen SA Rhabdomyosarcoma Drug Product Portfolio
  66. 7.11.5 Ipsen SA Recent Developments
  67. 7.12 Iproteos SL
  68. 7.12.1 Iproteos SL Company Information
  69. 7.12.2 Iproteos SL Business Overview
  70. 7.12.3 Iproteos SL Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Iproteos SL Rhabdomyosarcoma Drug Product Portfolio
  72. 7.12.5 Iproteos SL Recent Developments
  73. 7.13 Exelixis Inc
  74. 7.13.1 Exelixis Inc Company Information
  75. 7.13.2 Exelixis Inc Business Overview
  76. 7.13.3 Exelixis Inc Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Exelixis Inc Rhabdomyosarcoma Drug Product Portfolio
  78. 7.13.5 Exelixis Inc Recent Developments
  79. 7.14 Epizyme Inc
  80. 7.14.1 Epizyme Inc Company Information
  81. 7.14.2 Epizyme Inc Business Overview
  82. 7.14.3 Epizyme Inc Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Epizyme Inc Rhabdomyosarcoma Drug Product Portfolio
  84. 7.14.5 Epizyme Inc Recent Developments
  85. 7.15 Celgene Corp
  86. 7.15.1 Celgene Corp Company Information
  87. 7.15.2 Celgene Corp Business Overview
  88. 7.15.3 Celgene Corp Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Celgene Corp Rhabdomyosarcoma Drug Product Portfolio
  90. 7.15.5 Celgene Corp Recent Developments
  91. 7.16 Boehringer Ingelheim GmbH
  92. 7.16.1 Boehringer Ingelheim GmbH Company Information
  93. 7.16.2 Boehringer Ingelheim GmbH Business Overview
  94. 7.16.3 Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Product Portfolio
  96. 7.16.5 Boehringer Ingelheim GmbH Recent Developments
  97. 7.17 Bellicum Pharmaceuticals Inc
  98. 7.17.1 Bellicum Pharmaceuticals Inc Company Information
  99. 7.17.2 Bellicum Pharmaceuticals Inc Business Overview
  100. 7.17.3 Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Product Portfolio
  102. 7.17.5 Bellicum Pharmaceuticals Inc Recent Developments
8 North America
  1. 8.1 North America Rhabdomyosarcoma Drug Market Size by Type
  2. 8.1.1 North America Rhabdomyosarcoma Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Rhabdomyosarcoma Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Rhabdomyosarcoma Drug Price by Type (2021-2032)
  5. 8.2 North America Rhabdomyosarcoma Drug Market Size by Application
  6. 8.2.1 North America Rhabdomyosarcoma Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Rhabdomyosarcoma Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Rhabdomyosarcoma Drug Price by Application (2021-2032)
  9. 8.3 North America Rhabdomyosarcoma Drug Market Size by Country
  10. 8.3.1 North America Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Rhabdomyosarcoma Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Rhabdomyosarcoma Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Rhabdomyosarcoma Drug Market Size by Type
  2. 9.1.1 Europe Rhabdomyosarcoma Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Rhabdomyosarcoma Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Rhabdomyosarcoma Drug Price by Type (2021-2032)
  5. 9.2 Europe Rhabdomyosarcoma Drug Market Size by Application
  6. 9.2.1 Europe Rhabdomyosarcoma Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Rhabdomyosarcoma Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Rhabdomyosarcoma Drug Price by Application (2021-2032)
  9. 9.3 Europe Rhabdomyosarcoma Drug Market Size by Country
  10. 9.3.1 Europe Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Rhabdomyosarcoma Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Rhabdomyosarcoma Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Rhabdomyosarcoma Drug Market Size by Type
  2. 10.1.1 China Rhabdomyosarcoma Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Rhabdomyosarcoma Drug Sales by Type (2021-2032)
  4. 10.1.3 China Rhabdomyosarcoma Drug Price by Type (2021-2032)
  5. 10.2 China Rhabdomyosarcoma Drug Market Size by Application
  6. 10.2.1 China Rhabdomyosarcoma Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Rhabdomyosarcoma Drug Sales by Application (2021-2032)
  8. 10.2.3 China Rhabdomyosarcoma Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Rhabdomyosarcoma Drug Market Size by Type
  2. 11.1.1 Asia Rhabdomyosarcoma Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Rhabdomyosarcoma Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Rhabdomyosarcoma Drug Price by Type (2021-2032)
  5. 11.2 Asia Rhabdomyosarcoma Drug Market Size by Application
  6. 11.2.1 Asia Rhabdomyosarcoma Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Rhabdomyosarcoma Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Rhabdomyosarcoma Drug Price by Application (2021-2032)
  9. 11.3 Asia Rhabdomyosarcoma Drug Market Size by Country
  10. 11.3.1 Asia Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Rhabdomyosarcoma Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Rhabdomyosarcoma Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Rhabdomyosarcoma Drug Market Size by Type
  2. 12.1.1 SAMEA Rhabdomyosarcoma Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Rhabdomyosarcoma Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Rhabdomyosarcoma Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Rhabdomyosarcoma Drug Market Size by Application
  6. 12.2.1 SAMEA Rhabdomyosarcoma Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Rhabdomyosarcoma Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Rhabdomyosarcoma Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Rhabdomyosarcoma Drug Market Size by Country
  10. 12.3.1 SAMEA Rhabdomyosarcoma Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Rhabdomyosarcoma Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Rhabdomyosarcoma Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Rhabdomyosarcoma Drug Value Chain Analysis
  2. 13.1.1 Rhabdomyosarcoma Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Rhabdomyosarcoma Drug Production Mode & Process
  6. 13.2 Rhabdomyosarcoma Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Rhabdomyosarcoma Drug Distributors
  9. 13.2.3 Rhabdomyosarcoma Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst